All other authors do not have any financial disclosures relevant to the content of this manuscript.Ĭompeting interests: The commercial affiliation of author WH with OmegaQuant does not alter our adherence to PLOS ONE policies on sharing data and materials.ĭespite significant advances in the treatment of acute myocardial infarction (AMI), adverse left ventricular (LV) remodeling remains prevalent and is a key risk factor for cardiovascular (CV) death, ventricular arrhythmias, and progression to heart failure. The specific roles of these authors are articulated in the ‘author contributions’ section. OmegaQuant Analytics funder provided support in the form of salaries for author WSH, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: All relevant data are within the manuscript and its Supporting Information files.įunding: The OMEGA-REMODEL study was funded entirely by the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH R01HL091157). Received: ApAccepted: AugPublished: September 18, 2019Ĭopyright: © 2019 Kwong et al. PLoS ONE 14(9):Įditor: Giuseppe Andò, University of Messina, ITALY (2019) Genetic profiling of fatty acid desaturase polymorphisms identifies patients who may benefit from high-dose omega-3 fatty acids in cardiac remodeling after acute myocardial infarction-Post-hoc analysis from the OMEGA-REMODEL randomized controlled trial. The odds ratios for improving LVESVi by 10% with O-3FA treatment was 7.2, 1.6, and 1.2 in patients with GG, AG, and AA genotypes, respectively.Ĭitation: Kwong RY, Heydari B, Ge Y, Abdullah S, Fujikura K, Kaneko K, et al. In contrast, patients with either AA or AG genotype did not demonstrate significant lowering of LVESVi, NT-proBNP, or galectin-3 levels from O-3FA treatment, compared to placebo. When randomized to 6-months of O-3FA treatment, GG patients demonstrated significant lowering of LV end-systolic volume index (LVESVi), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), and galectin-3 levels compared to placebo (-4.4 vs. Consistent with known genetic polymorphism of FADS2, patients in our cohort with the guanine-guanine (GG) genotype had the lowest FADS2 activity assessed by arachidonic acid/linoleic acid (ArA/LA) ratio, compared with patients with the adenine-adenine (AA) and adenine-guanine (AG) genotypes (GG:1.62☐.35 vs. We tested the hypothesis that the genotypic status of FADS2 (rs1535) modifies therapeutic response of O-3FA in post-AMI cardiac remodeling in 312 patients.
0 Comments
Leave a Reply. |